Application of non-lactolytic streptococci in the preparation of products for preventing obesity

Abstract

This invention discloses the application of non-lactolytic streptococci in the preparation of products for preventing obesity, belonging to the field of animal nutrition and feed science and technology. This invention involves preparing non-lactolytic streptococci CCUG41503 into a concentration of 1×10⁻⁶. 8 When a CFU / mL bacterial suspension was administered via gavage to broilers and obese mice, *Streptococcus non-lactolyticus* CCUG41503 reduced abdominal fat percentage and the diameter and area of ​​adipocytes in broilers, and also reduced the weight of epididymal white fat and the diameter and area of ​​adipocytes in obese mice. This indicates that *Streptococcus non-lactolyticus* CCUG41503 has a fat-reducing effect and is widely applicable across multiple species.

Description

Technical Field

[0001] This invention relates to the field of animal nutrition and feed science and technology, and in particular to the application of non-lactose-degrading streptococci in the preparation of products for preventing obesity. Background Technology

[0002] Currently, excessive fat deposition has become a major challenge in animal production and human health. In humans, visceral fat accumulation is considered a marker of obesity and is closely associated with metabolic diseases such as type 2 diabetes, hypertension, and cardiovascular disease. In livestock and poultry production, excessive abdominal fat deposition in broilers reduces feed utilization efficiency and increases production costs. Furthermore, it increases the risk of metabolic diseases, impacting broiler health and production sustainability. Therefore, reducing fat deposition is crucial for improving animal production efficiency and addressing related human health issues.

[0003] Current technologies for addressing lipid deposition mainly focus on nutritional regulation, genetic selection, and microbial intervention. Nutritional regulation includes low-carbohydrate diets and the use of functional additives, but these methods often suffer from drawbacks such as long cycles, high costs, and potential negative impacts on animal growth performance. Genetic selection, through the breeding of low-fat strains, has made some progress, but its long breeding cycle presents challenges for practical application. Recent studies have shown that the microbiome plays a crucial role in regulating lipid metabolism, and certain probiotics have demonstrated potential applications in regulating lipid metabolism. Therefore, microbial intervention, as an emerging regulatory approach, offers a new perspective on solving the problem of excessive lipid deposition. Summary of the Invention

[0004] The purpose of this invention is to provide the application of *Streptococcus non-lactolyticus* in the preparation of products for preventing obesity, thereby addressing the problems existing in the prior art. This invention utilizes broiler chicken and obese mouse models to determine that *Streptococcus non-lactolyticus* CCUG41503 can serve as a functional probiotic to alleviate fat deposition and prevent obesity and metabolic diseases.

[0005] To achieve the above objectives, the present invention provides the following solution:

[0006] One of the technical solutions of this invention is the application of non-lactolytic streptococci in the preparation of products for preventing obesity.

[0007] The second technical solution of the present invention is a product for preventing obesity, comprising non-lactolytic streptococci CCUG41503.

[0008] Based on the above technical solution, the present invention has the following technical effects:

[0009] This invention involves preparing non-lactolytic streptococci CCUG41503 at a concentration of 1×10⁻⁶.8 When a CFU / mL bacterial suspension was administered via gavage to broilers and obese mice, *Streptococcus non-lactolyticus* CCUG41503 reduced abdominal fat percentage and the diameter and area of ​​adipocytes in broilers, and also reduced the weight of epididymal white fat and the diameter and area of ​​adipocytes in obese mice. This indicates that *Streptococcus non-lactolyticus* CCUG41503 has a fat-reducing effect and is widely applicable across multiple species. Attached Figure Description

[0010] To more clearly illustrate the technical solutions in the embodiments of the present invention or the prior art, the drawings used in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For those skilled in the art, other drawings can be obtained based on these drawings without creative effort.

[0011] Figure 1 This image shows the H&E staining of abdominal adipose tissue in broilers and the statistical analysis of adipocyte diameter and area. Figure A shows the anatomical and H&E staining diagram of the abdominal adipose tissue; Figure B shows the statistical analysis of adipocyte diameter; and Figure C shows the statistical analysis of adipocyte cross-sectional area.

[0012] Figure 2 The effects of gavage administration of non-lactolytic streptococci (CCUG41503) on body weight and blood lipid levels in obese mice were investigated. In this study, A represents mouse body weight, B represents average food intake, and C represents serum triglyceride, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and glucose levels.

[0013] Figure 3 This study investigated the effect of oral administration of non-lactolytic streptococci (CCUG41503) on white adipose tissue deposition in the epididymis of obese mice. Figure A shows an anatomical diagram and H&E staining of epididymal white adipose tissue; B shows total fat weight; C shows total fat percentage (total fat percentage (%) = total fat weight / body weight × 100%); D shows the weight of epididymal white adipose tissue; E shows the epididymal white adipose percentage (epididymal white adipose percentage (%) = epididymal white adipose tissue weight / body weight × 100%); F shows a statistical graph of adipocyte diameter; and G shows a statistical graph of adipocyte cross-sectional area. Detailed Implementation

[0014] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as a limitation of the present invention, but rather as a more detailed description of certain aspects, features, and embodiments of the present invention.

[0015] It should be understood that the terminology used in this invention is merely for describing particular embodiments and is not intended to limit the invention. Furthermore, with respect to numerical ranges in this invention, it should be understood that each intermediate value between the upper and lower limits of the range is also specifically disclosed. Every smaller range between any stated value or intermediate value within a stated range, and any other stated value or intermediate value within said range, is also included in this invention. The upper and lower limits of these smaller ranges may be independently included or excluded from the range.

[0016] Unless otherwise stated, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art. While only preferred methods and materials have been described herein, any methods and materials similar or equivalent to those described herein may be used in the implementation or testing of this invention. All references to this specification are incorporated by way of citation to disclose and describe methods and / or materials associated with those references. In the event of any conflict with any incorporated reference, the content of this specification shall prevail.

[0017] Various modifications and variations can be made to the specific embodiments described in this specification without departing from the scope or spirit of the invention, as will be apparent to those skilled in the art. Other embodiments derived from this specification will also be obvious to those skilled in the art. This application specification and embodiments are merely exemplary.

[0018] The terms “include,” “including,” “have,” “contain,” etc., used in this article are all open-ended terms, meaning that they include but are not limited to.

[0019] Unless otherwise specified, the technical solutions described in this invention are all conventional solutions in the field, and the reagents or raw materials used are all purchased from commercial channels or are publicly available unless otherwise specified.

[0020] This invention provides the application of non-lactolytic streptococci in the preparation of products for preventing obesity.

[0021] In some specific implementations, the non-lactolytic streptococci play a role in reducing fat and preventing obesity by lowering abdominal fat percentage, body weight, and the levels of total cholesterol and triglycerides in serum.

[0022] This invention also provides a product for preventing obesity, comprising non-lactose-degrading streptococci.

[0023] This invention addresses the limitations of existing technologies in regulating lipid deposition by proposing a more efficient and feasible solution. Current nutritional regulation methods (such as low-carbohydrate diets and functional additives) can reduce lipid deposition to some extent, but they suffer from drawbacks such as long regulation cycles, high production costs, and potential adverse effects on animal growth performance. While genetic breeding can produce low-fat strains, its long breeding cycle and limited genetic improvement efficiency make it difficult to meet practical production needs. Furthermore, microbial intervention, as an emerging strategy, has shown potential regulatory effects on lipid metabolism, but current research is still in its early stages; the screening of suitable strains and their specific mechanisms of action remain unclear, limiting its application in production. The purpose of this invention is to overcome the shortcomings of existing methods and provide an efficient, low-cost, and feasible means of regulating lipid deposition to optimize animal lipid metabolism, improve production performance, and reduce the risk of metabolic diseases related to lipid deposition, thereby enhancing the sustainable development of livestock and poultry farming.

[0024] The non-lactolytic streptococcus used in this invention was purchased from Ningbo Mingzhou Biotechnology Co., Ltd., with the product number CCUG41503 (https: / / www.ccug.se / strain?id=41503&s=0&p=1&sort=rel&collection=entire&records=25&t=41503).

[0025] Example 1

[0026] Effects of gavage administration of non-lactose-degrading streptococci on growth performance and abdominal fat percentage in broilers.

[0027] First, the *Streptococcus non-lactolyticus* strain was activated to prepare a gavage suspension. The specific method was as follows: *Streptococcus non-lactolyticus* CCUG41503 was inoculated into BHI broth at a ratio of 2% (v / v) and activated for three generations at 37°C before amplification culture. The amplified bacterial suspension was centrifuged at 4,000 rpm, 4°C for 15 min, and the cells were washed twice with sterile PBS and collected by centrifugation at 4,000 rpm, 4°C for 15 min. Finally, the suspension was diluted with sterile PBS to adjust the viable count to 1 × 10⁻⁶. 8 CFU / mL was used for subsequent gavage in broiler chickens and mice.

[0028] Two hundred 1-day-old Arbor Acqua (AA) broiler chickens (half male and half female) with similar weights were selected and randomly divided into a control group (CON) and a bacterial culture feeding group (SA) using a single-factor completely randomized experimental design.

[0029] During the trial, broilers had free access to feed and water, and received routine immunizations. Starting at 14 days of age, the SA group received 1×10 mg of [a specific medication / treatment] daily. 8The CFU / mL dose was administered via gavage of 1 mL of non-lactolytic streptococci CCUG41503, while the CON group was administered the same amount of PBS via gavage daily.

[0030] Growth performance was assessed at 28 days of age, followed by slaughter to collect abdominal adipose tissue, measure its weight, and calculate abdominal fat percentage. The results (see Table 1) showed that gavage administration of non-lactolytic streptococci CCUG41503 had no effect on body weight, average daily feed intake, average daily gain, or feed conversion ratio in broilers aged 1-14 days, 14-28 days, and 1-28 days. However, it reduced the abdominal fat percentage at 28 days of age, and the abdominal adipose tissue was significantly thinner, with a significant decrease in the diameter and area of ​​adipocytes (see Table 1). Figure 1 ).

[0031] Table 1. Effects of gavage administration of non-lactolytic streptococcus citrate CCUG41503 on broiler growth performance.

[0032]

[0033]

[0034] Example 2

[0035] Effects of gavage administration of non-lactolytic streptococci CCUG41503 on obese mice.

[0036] Seven-week-old germ-free male C57BL / 6J mice were used in the experiment and were obtained from Chengdu Bosai Experimental Animal Co., Ltd. All mice were fed a standard diet for one week before the start of the formal experiment. Forty-eight male C57BL / 6J mice were randomly divided into three groups (n=16): the control group (CON) was fed a normal diet, the high-fat group (HFD), and the bacterial culture gavage group (HFD+SA) were fed a 60% high-fat diet.

[0037] HFD+SA group: 1×10 daily 8 0.2 mL of non-lactolytic streptococci (CCUG41503) were administered via gavage at a dose of CFU / mL. The CON and HFD groups received an equal volume of PBS via gavage. Treatment lasted for 7 weeks, during which individual body weight and food intake were measured weekly.

[0038] After the experiment, serum was obtained by centrifuging blood from the orbital venous plexus of mice. The mice were then dissected, and white adipose tissue from the epididymis was collected, weighed, and the fat percentage was calculated.

[0039] The results showed that gavage administration of non-lactolytic streptococci CCUG41503 had no effect on the average food intake of obese mice, but significantly reduced the body weight and serum total cholesterol and triglyceride levels in obese mice (see [link to study]). Figure 2Furthermore, gavage administration of non-lactolytic streptococci CCUG41503 significantly reduced the content of epididymal white adipose tissue in obese mice, and the diameter and area of ​​adipocytes were significantly reduced (see [link to original text]). Figure 3 ).

[0040] Obviously, the above embodiments of the present invention are merely examples for clearly illustrating the present invention, and are not intended to limit the implementation of the present invention. For those skilled in the art, other variations or modifications can be made based on the above description. It is neither necessary nor possible to exhaustively describe all embodiments here. Any modifications, equivalent substitutions, and improvements made within the spirit and principles of the present invention should be included within the scope of protection of the claims of the present invention.

Claims

1. Use of non-lactose fermenting Streptococcus in the preparation of a product for preventing obesity, characterized in that, The non-lactose-fermenting Streptococcus is purchased from Ningbo Mingzhou Biotechnology Co., Ltd., and the number is CCUG41503.

2. Use according to claim 1, characterized in that, The non-lactose-fermenting Streptococcus plays a role in reducing fat and preventing obesity by reducing the abdominal fat rate, body weight, and the content of total cholesterol and triglyceride in serum.

Images